Denali Therapeutics
DNLI
DNLI
187 hedge funds and large institutions have $2.73B invested in Denali Therapeutics in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 72 increasing their positions, 57 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
187
Holders Change
-2
Holders Change %
-1.06%
% of All Funds
3.16%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
21
Increased
72
Reduced
57
Closed
19
Calls
$1.82M
Puts
$561K
Net Calls
+$1.26M
Net Calls Change
+$2.24M
Top Buyers
| 1 |
AVM
1
Arch Venture Management
Chicago,
Illinois
|
$152M |
| 2 |
2
Marshall Wace
London,
United Kingdom
|
$24.1M |
| 3 |
3
Millennium Management
New York
|
$19M |
| 4 |
4
BlackRock
New York
|
$259M |
| 5 |
BBA
5
Baker Bros. Advisors
New York
|
$17.3M |
Top Sellers
| 1 |
GGHC
1
Gilder Gagnon Howe & Co
New York
|
$57.6M |
| 2 |
2
Citadel Advisors
Miami,
Florida
|
$9.01M |
| 3 |
3
BAMCO Inc
New York
|
$8.11M |
| 4 |
4
T. Rowe Price Associates
Baltimore,
Maryland
|
$136M |
| 5 |
5
Morgan Stanley
New York
|
$12.4M |
